Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PLS011
MIFTS: 57

Plasmacytoma

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Plasmacytoma

About this section

MalaCards integrated aliases for Plasmacytoma:

Name: Plasmacytoma 11 19 58 53 43 14 16 71 75
Solitary Plasmacytoma 11 19 58 31 33
Solitary Myeloma 11 33
Solitary Plasmacytoma Without Mention of Remission 33
Localised Malignant Plasma Cell Tumour Nos 33
Solitary Osseous Plasmacytoma 71
Plasmacytoma - Category 71
Myeloma - Solitary 11
Myeloma, Solitary 11
Plasmacytoma Nos 33

Characteristics:


Prevelance:

1-9/1000000 (United States) 58

Age Of Onset:

Adult 58

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases Blood diseases Immune diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 31 32
ICD11: 33
Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


External Ids:

Disease Ontology 11 DOID:3721
MeSH 43 D010954
NCIt 49 C9349
SNOMED-CT 68 302852008
ICD10 31 C90.3
MESH via Orphanet 44 D010954
ICD10 via Orphanet 32 C90.2 C90.3
UMLS via Orphanet 72 C0032131
Orphanet 58 ORPHA86855
ICD11 33 1811140613
UMLS 71 C0032131 C0272256 C1532560
Sources

Summaries for Plasmacytoma

About this section

Orphanet: 58 Plasmacytoma is a localized mass of neoplastic monoclonal plasma cells that represents approximately 5% of all plasma cell neoplasms. There are two separate entities: primary plasmacytoma of the bone and extramedullary plasmacytoma of the soft tissues. Of the extramedullary plasmacytomas, 80% occur in the head and neck, usually in the upper respiratory tract. The median age at diagnosis is 50 years and the male to female ratio is 3:1. Long-term survival is possible following local radiotherapy, particularly for soft tissue presentations.

MalaCards based summary: Plasmacytoma, also known as solitary plasmacytoma, is related to solitary osseous plasmacytoma and extramedullary plasmacytoma, and has symptoms including bone pain An important gene associated with Plasmacytoma is PVT1 (Pvt1 Oncogene), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Lenograstim and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Reduced mammosphere formation and nervous system

Wikipedia: 75 Plasmacytoma is a plasma cell dyscrasia in which a plasma cell tumour grows within soft tissue or within... more...
Sources

Related Diseases for Plasmacytoma

About this section

Diseases related to Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 720)
# Related Disease Score Top Affiliating Genes
1 solitary osseous plasmacytoma 32.4 PTPRC NCAM1 CD79A CD38 B2M
2 extramedullary plasmacytoma 32.4 PTPRC PAX5 NCAM1 CD79A CD38 CCND1
3 plasmablastic lymphoma 31.9 PAX5 MYC CD79A CD38
4 plasma cell neoplasm 31.5 PVT1 PTPRC PAX5 NCAM1 MYC IL6
5 amyloidosis 31.4 IL6 IGKC CCND1 B2M
6 myeloma, multiple 31.4 PVT1 PTPRC PAX5 OSM NCAM1 MYC
7 castleman disease 31.1 IL6ST IL6R IL6
8 b-cell lymphoma 30.8 PVT1 PTPRC PAX5 MYC CCND1 BCL2
9 plasma cell leukemia 30.8 NCAM1 IL6 CD38 CCND1 B2M
10 macroglobulinemia 30.7 PAX5 IL6 BCL2
11 lymphoma, hodgkin, classic 30.7 PVT1 PTPRC PAX5 BCL2
12 burkitt lymphoma 30.6 PVT1 PAX5 MYC IL6 BCL2 B2M
13 lymphoma 30.6 PVT1 PTPRC PAX5 MYC IL6 CD38
14 osteogenic sarcoma 30.6 PVT1 MYC IL6 IL11
15 deficiency anemia 30.6 PTPRC LIF IL6 IL11 CD38 B2M
16 kaposi sarcoma 30.6 OSM IL6ST IL6R IL6
17 monoclonal gammopathy of uncertain significance 30.5 PTPRC NCAM1 MYC IL6 CD38 CCND1
18 colonic benign neoplasm 30.5 MYC IL6 CCND1 BCL2
19 acquired immunodeficiency syndrome 30.4 MYC IL6 CD79A CD38 CCND1 BCL2
20 lymphoma, mucosa-associated lymphoid type 30.4 PAX5 MYC IGKC CD79A CCND1 BCL2
21 paraganglioma 30.4 NCAM1 IL6 CCND1 BCL2
22 diffuse large b-cell lymphoma 30.4 PAX5 MYC CD79A BCL2
23 peripheral nervous system disease 30.4 PTPRC NCAM1 MYC IL6 CCND1 BCL2
24 immune deficiency disease 30.4 PTPRC IL6R IL6 CD79A CD38 B2M
25 orbital cancer 30.3 NCAM1 BCL2
26 ewing sarcoma 30.3 PTPRC NCAM1 MYC LIF CCND1
27 marginal zone b-cell lymphoma 30.3 PAX5 MYC CD79A CD38 CCND1 BCL2
28 testicular disease 30.3 MYC IL6 BCL2
29 waldenstroem's macroglobulinemia 30.3 PTPRC PAX5 CD38 CCND1 B2M
30 leukemia, chronic myeloid 30.3 PTPRC MYC IL6 IL11 CD38 CCND1
31 myeloid sarcoma 30.2 PTPRC NCAM1 CD79A
32 gallbladder disease 30.2 MYC IL6 CCND1 BCL2
33 monoclonal paraproteinemia 30.2 PAX5 NCAM1 CD79A B2M
34 orbital cellulitis 30.2 NCAM1 IL6
35 thrombocytosis 30.2 LIF IL6 IL11
36 leukemia 30.1 STMN1 OSM MYC LIF IL6ST CD38
37 epiglottis neoplasm 30.1 PTPRC CD79A
38 composite lymphoma 30.1 PAX5 CD79A BCL2
39 head and neck cancer 30.1 MYC IL6 CCND1 BCL2
40 cryoglobulinemia 30.1 IL6 CD79A BCL2
41 chronic kidney disease 30.0 PAX5 IL6R IL6 CD79A B2M
42 mediastinal cancer 30.0 PAX5 NCAM1 CD79A
43 non-secretory myeloma 30.0 NCAM1 CD38 B2M
44 leukemia, chronic lymphocytic 2 30.0 CD38 BCL2
45 leukemia, acute myeloid 30.0 PTPRC PAX5 NCAM1 MYC IL6 CD79A
46 keratoacanthoma 29.9 OSM MYC BCL2
47 type 1 diabetes mellitus 29.9 PVT1 PTPRC IL6 CD79A B2M
48 celiac disease 1 29.9 PTPRC NCAM1 IL6 CD79A
49 mature t-cell and nk-cell lymphoma 29.9 PAX5 NCAM1 MYC CD79A BCL2
50 gastrointestinal stromal tumor 29.9 NCAM1 MYC CCND1 BCL2

Graphical network of the top 20 diseases related to Plasmacytoma:



Diseases related to Plasmacytoma
Sources

Symptoms & Phenotypes for Plasmacytoma

About this section

UMLS symptoms related to Plasmacytoma:


bone pain

GenomeRNAi Phenotypes related to Plasmacytoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.23 CCND1 CD79A EBF1 IL6R IL6ST MYC

MGI Mouse Phenotypes related to Plasmacytoma:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.35 B2M BCL2 CCND1 CD79A EBF1 IL6
2 homeostasis/metabolism MP:0005376 10.28 B2M BCL2 CCND1 CD38 CD79A IL6
3 neoplasm MP:0002006 10.19 B2M BCL2 CCND1 CD79A IL6 IL6R
4 cellular MP:0005384 10.17 B2M BCL2 CCND1 CD38 CD79A EBF1
5 liver/biliary system MP:0005370 10.11 B2M CD79A EBF1 IL6 IL6R IL6ST
6 endocrine/exocrine gland MP:0005379 10.1 B2M BCL2 CCND1 CD38 IL6 IL6R
7 cardiovascular system MP:0005385 10 B2M BCL2 CCND1 EBF1 IL6 IL6ST
8 immune system MP:0005387 10 B2M BCL2 CCND1 CD38 CD79A EBF1
9 digestive/alimentary MP:0005381 9.97 B2M BCL2 CCND1 IL6 IL6ST LIF
10 hematopoietic system MP:0005397 9.83 B2M BCL2 CCND1 CD38 CD79A EBF1
11 integument MP:0010771 9.32 B2M BCL2 CCND1 EBF1 IL6 IL6ST
Sources

Drugs & Therapeutics for Plasmacytoma

About this section

Drugs for Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
3 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
4
Carmustine Approved, Investigational Phase 3 154-93-8 2578
5
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
6
Melphalan Approved Phase 3 148-82-3 4053 460612
7
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
8
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
9
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
10
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
11
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
12
Amitriptyline Approved Phase 3 50-48-6 2160
13
Baclofen Approved Phase 3 1134-47-0 2284
14
Ketamine Approved, Vet_approved Phase 3 6740-88-1, 1867-66-9 3821
15
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2
16
Ondansetron Approved, Withdrawn Phase 3 99614-02-5 4595
17
Pamidronic acid Approved Phase 3 40391-99-9 4674
18
Heparin, bovine Approved, Investigational, Withdrawn Phase 3 9005-49-6 22833565 9812414 772
19
Reviparin Approved, Investigational Phase 3 9041-08-1
20
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 3 14838-15-4, 492-39-7 131954576 4786 26934
21
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
22
Morphine Approved, Investigational Phase 3 57-27-2 5288826
23
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
24
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965
25
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
26
Deoxycholic acid Approved Phase 3 83-44-3 222528
27
Idarubicin Approved Phase 3 58957-92-9 42890
28
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
29
Vancomycin Approved Phase 3 1404-90-6 14969
30
Tazobactam Approved Phase 3 89786-04-9 123630
31
Piperacillin Approved Phase 3 66258-76-2 43672
32
Ixazomib Approved, Investigational Phase 3 1072833-77-2 25183872
33
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
34
Ethinylestradiol Approved Phase 3 57-63-6 5991
35
Polyestradiol phosphate Approved Phase 3 28014-46-2
36
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
37
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
38
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
39
Glutaral Experimental Phase 3 111-30-8 3485
40
Oblimersen Experimental, Investigational Phase 3 190977-41-4
41 Blood Substitutes Phase 3
42 Ferric Oxide, Saccharated Phase 3
43 Iron-Dextran Complex Phase 3
44 Plasma Substitutes Phase 3
45 Dextrans Phase 3
46 Hormones Phase 3
47 Hormone Antagonists Phase 3
48 Anti-Inflammatory Agents Phase 3
49 glucocorticoids Phase 3
50 Respiratory System Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 358)
# Name Status NCT ID Phase Drugs
1 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Influenza Vaccination in Plasma Cell Dyscrasias Active, not recruiting NCT04080531 Phase 4
3 Study of Cyclophosphamide，Liposome Doxorubicin Dexamethasone（CDD) Plus Bortezomib Compared With CDD in the Relapsed or Refractory Multiple Myeloma Combined With Extramedullary Plasmacytoma Patients Unknown status NCT02336386 Phase 3 CDD;CDD Plus Bortezomib
4 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
5 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
6 Randomized Controlled Study of Iron Supplementation to Support the Response to Recombinant Human Erythropoietin for the Treatment of Chemotherapy-Induced Anaemia Unknown status NCT00482716 Phase 3
7 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
8 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
9 A Randomized Phase III Study to Assess Intensification of the Conditioning Regimen for Allogenic Stem Cell Transplantation (ALLO-SCT) for Leukemia or Myelodysplastic Syndrome With a High Risk of Relapse Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
10 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
11 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
12 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
13 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
14 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
15 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
16 Phase III Trial of Stem Cell Transplantation Compared to Parenteral Melphalan and Oral Dexamethasone in the Treatment of Primary Systemic Amyloidosis (AL) Completed NCT00477971 Phase 3 dexamethasone;melphalan
17 The Use of Topical Baclofen, Amitriptyline HCI, and Ketamine (BAK) in a PLO Gel vs. Placebo for the Treatment of Chemotherapy Induced Peripheral Neuropathy: A Phase III Randomized Double-Blind Placebo Controlled Study Completed NCT00516503 Phase 3 baclofen/amitriptyline/ketamine gel
18 A Randomised Controlled Trial of Adjunctive Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Renal Failure [MERIT] MyEloma Renal Impairment Trial Completed NCT00416897 Phase 3 chemotherapy;dexamethasone
19 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
20 Randomized Placebo Controlled Double Blind Study of Restasis Versus Placebo in Primary Prevention of Ocular GVHD After Allogeneic Stem Cell Transplantation Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
21 A Phase III Randomized Trial of Thalidomide Plus Zoledronic Acid Versus Zoledronic Acid Alone in Patients With Early Stage Multiple Myeloma Completed NCT00432458 Phase 3 Thalidomide;zoledronic acid
22 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
23 A PROSPECTIVE RANDOMIZED, DOUBLE-BLIND, COMPARATIVE, MULTICENTER STUDY TO EVALUATE EFFICACY AND SAFETY OF NYSTATIN AND AMPHOTERICIN B FOR EMPIRIC ANTIFUNGAL TREATMENT IN NEUTROPENIC PATIENTS Completed NCT00002742 Phase 3 amphotericin B deoxycholate;nystatin
24 Phase III Trial Comparing Dexamethasone (DEX) to the Combination of DEX + CC-5013 in Patients With Previously Untreated Multiple Myeloma Completed NCT00064038 Phase 3 dexamethasone;lenalidomide
25 A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma Completed NCT00033332 Phase 3 dexamethasone;pamidronate disodium;thalidomide;zoledronic acid
26 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
27 A Randomized Trial Comparing Z-Dex With VAD as Induction Therapy for Patients With Multiple Myeloma Completed NCT00006232 Phase 3 dexamethasone;doxorubicin hydrochloride;idarubicin;vincristine sulfate
28 Comparative Study of Dexamethasone vs Prednisone (Both in Combination With Melphalan) as Induction Therapy in Untreated Symptomatic Myeloma With an Additional Assessment of Dexamethasone vs no Additional Treatment as Maintenance Therapy in Non-Progressing Patients Completed NCT00002678 Phase 3 dexamethasone;melphalan;prednisone
29 A Phase III, Randomized Study Of Two Different Dosing Schedules Of Erythropoetin In Anemic Patients With Cancer Completed NCT00058331 Phase 3
30 Stem Cell Transplant as Standard Therapy for Symptomatic Multiple Myeloma Completed NCT00004165 Phase 3 melphalan
31 A Phase III Randomized Double-Blind Study of Erythropoietin Versus Placebo in Anemic Patients With Cancer Undergoing Chemotherapy Completed NCT00003600 Phase 3
32 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
33 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
34 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
35 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
36 A PHASE III STUDY OF PSC-833 IN COMBINATION WITH VINCRISTINE, DOXORUBICIN AND DEXAMETHASONE (PSC-833/VAD) VERSUS VAD ALONE IN PATIENTS WITH RELAPSING OR REFRACTORY MULTIPLE MYELOMA Completed NCT00002878 Phase 3 dexamethasone;doxorubicin hydrochloride;valspodar;vincristine sulfate
37 Phase III Trial of T Lymphocyte Depletion by Elutriation and CD34 Add-Back for Allogeneic Bone Marrow Transplantation Completed NCT00265837 Phase 3
38 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
39 A Randomized Phase III Study Of Thalidomide And Prednisone As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients With Multiple Myeloma Completed NCT00049673 Phase 3 prednisone;thalidomide
40 Randomized Phase III Study of Dexamethasone With or Without Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00017602 Phase 3 dexamethasone
41 A Phase III Multicenter, Randomized, Open-Label Trial Evaluating High Dose Melphalan Plus Holmium-166-DOTMP Versus High Dose Melphalan Alone When Given In Conjuction With Peripheral Blood Stem Cell Transplantation In Patients With Multiple Myeloma Completed NCT00008229 Phase 3 melphalan
42 Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma Active, not recruiting NCT02544308 Phase 3 Lenalidomide;Dexamethasone
43 Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment With Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy Active, not recruiting NCT02516423 Phase 3 ixazomib;lenalidomide;dexamethasone;zoledronic acid
44 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
45 A Phase II Trial to Evaluate the Efficacy of Daratumumab With DCEP in Multiply Myeloma Patients With Plasmacytoma Who Fail to Achieve Complete Remission With Bortezomib Containing Induction Regimen Unknown status NCT04065308 Phase 2 Drug Combinations
46 A Randomised, International, Open-label, Phase II Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization and Engraftment With Pegfilgrastim or Filgrastim for Autologous Transplantation in Patients With Multiple Myeloma (MM) Unknown status NCT00526734 Phase 2 melphalan
47 A Phase II Trial With VELCADE® (PS-341), Cytoxan (Cyclophosphamide), Dexamethasone and Thalomid® (VEL-CTD) in Previously Untreated Multiple Myeloma Patients Unknown status NCT00438841 Phase 2 bortezomib;cyclophosphamide;dexamethasone;thalidomide
48 Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy Unknown status NCT00389701 Phase 2 bortezomib;dexamethasone
49 A Phase II Study of Pegylated Liposomal Doxorubicin, Bortezomib and Dexamethasone (DVD) for Patients With Newly Diagnosed Multiple Myeloma (MM) Unknown status NCT00742404 Phase 2 bortezomib;dexamethasone;pegylated liposomal doxorubicin hydrochloride
50 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil

Search NIH Clinical Center for Plasmacytoma

Cochrane evidence based reviews: plasmacytoma

Sources

Genetic Tests for Plasmacytoma

About this section
Sources

Anatomical Context for Plasmacytoma

About this section

Organs/tissues related to Plasmacytoma:

MalaCards : Bone, Bone Marrow, T Cells, B Cells, Myeloid, Liver, Breast
Sources

Publications for Plasmacytoma

About this section

Articles related to Plasmacytoma:

(show top 50) (show all 6248)
# Title Authors PMID Year
1
IL-6: from its discovery to clinical applications. 53 62
20410258 2010
2
Targeting activation-induced cytidine deaminase overcomes tumor evasion of immunotherapy by CTLs. 53 62
20404277 2010
3
IL-6 and MYC collaborate in plasma cell tumor formation in mice. 53 62
20018915 2010
4
Opposing effects of SWI/SNF and Mi-2/NuRD chromatin remodeling complexes on epigenetic reprogramming by EBF and Pax5. 53 62
19549820 2009
5
The 'zinc knuckle' motif of Early B cell Factor is required for transcriptional activation of B cell-specific genes. 53 62
18606452 2008
6
Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice. 53 62
18648000 2008
7
Induction of apoptosis in plasma cells by B lymphocyte-induced maturation protein-1 knockdown. 53 62
18089822 2007
8
Identification of ERdj3 and OBF-1/BOB-1/OCA-B as direct targets of XBP-1 during plasma cell differentiation. 53 62
17709512 2007
9
c-Myc-dependent formation of Robertsonian translocation chromosomes in mouse cells. 53 62
17710161 2007
10
Anaplastic, plasmablastic, and plasmacytic plasmacytomas of mice: relationships to human plasma cell neoplasms and late-stage differentiation of normal B cells. 53 62
17363561 2007
11
Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. 53 62
17119059 2006
12
Myc translocations in B cell and plasma cell neoplasms. 53 62
16815105 2006
13
[Expression of B cell-specific activator protein in lymphomas]. 53 62
16185503 2005
14
Extraosseous IL-6 transgenic mouse plasmacytoma sometimes lacks Myc-activating chromosomal translocation. 53 62
15751044 2005
15
Up-date on solitary plasmacytoma and its main differences with multiple myeloma. 53 62
15812350 2005
16
Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. 53 62
15735016 2005
17
RT-PCR analysis of RNA extracted from Bouin-fixed and paraffin-embedded lymphoid tissues. 53 62
15507667 2004
18
Early B cell factor cooperates with Runx1 and mediates epigenetic changes associated with mb-1 transcription. 53 62
15361869 2004
19
Activation of the early B-cell-specific mb-1 (Ig-alpha) gene by Pax-5 is dependent on an unmethylated Ets binding site. 53 62
12612069 2003
20
The value of anti-pax-5 immunostaining in routinely fixed and paraffin-embedded sections: a novel pan pre-B and B-cell marker. 53 62
12360049 2002
21
CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells. 53 62
12685844 2002
22
MEK inhibitor U0126 interferes with immunofluorescence analysis of apoptotic cell death. 53 62
12210141 2002
23
Bob1 (OCA-B/OBF-1) differential transactivation of the B cell-specific B29 (Ig beta) and mb-1 (Ig alpha) promoters. 53 62
11907094 2002
24
IL-6 transgenic mouse model for extraosseous plasmacytoma. 53 62
11805288 2002
25
IL-11: insights in asthma from overexpression transgenic modeling. 53 62
11590369 2001
26
Unique function for carboxyl-terminal domain of Oct-2 in Ig-secreting cells. 53 62
11591767 2001
27
No involvement of Erk/MAP kinases in IL-6-induced proliferation of a B cell hybridoma cell line. 53 62
11556393 2001
28
Translocation remodeling in the primary BALB/c plasmacytoma TEPC 3610. 53 62
11170286 2001
29
Localized amyloidosis and extramedullary plasmacytoma involving the larynx of a child. 53 62
11172308 2001
30
The phosphatidylinositol 3-kinase/AKT kinase pathway in multiple myeloma plasma cells: roles in cytokine-dependent survival and proliferative responses. 53 62
11118064 2000
31
The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. 53 62
11090073 2000
32
Lymph nodes and Peyer's patches of IL-6 transgenic BALB/c mice harbor T(12;15) translocated plasma cells that contain illegitimate exchanges between the immunoglobulin heavy-chain mu locus and c-myc. 53 62
10865979 2000
33
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma. 53 62
10618400 2000
34
Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry IgH and myc genes. 53 62
10570182 1999
35
Uterine milk protein, a novel activin-binding protein, is present in ovine allantoic fluid. 53 62
10499534 1999
36
Three unrelated viral transforming proteins (vIRF, EBNA2, and E1A) induce the MYC oncogene through the interferon-responsive PRF element by using different transcription coadaptors. 53 62
10500217 1999
37
Metastatic cutaneous plasmacytoma: a case report associated with IgA lambda multiple myeloma and a review of the literature of metastatic cutaneous plasmacytomas associated with multiple myeloma and primary cutaneous plasmacytomas. 53 62
10535253 1999
38
Hematopoietic differentiation activity of a recombinant human interleukin-6 (IL-6) isoform resulting from alternatively spliced deletion of the second exon. 53 62
10398309 1999
39
Castleman's disease. 53 62
10655569 1999
40
Human chromosome 21 determines growth factor dependence in human/mouse B-cell hybridomas. 53 62
9661903 1998
41
Interleukin-6 receptor-interleukin-6 fusion proteins with enhanced interleukin-6 type pleiotropic activities. 53 62
9459615 1997
42
Role of interleukin-6 in the pathogenesis of murine plasmacytoma and human multiple myeloma. 53 62
9284811 1997
43
Defective development of pristane-oil-induced plasmacytomas in interleukin-6-deficient BALB/c mice. 53 62
9284817 1997
44
Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation. 53 62
9110979 1997
45
Concomitant downregulation of IgH 3' enhancer activity and c-myc expression in a plasmacytoma x fibroblast environment: implications for dysregulation of translocated c-myc. 53 62
9188842 1997
46
Ig/myc translocations of the plasmacytoma-prone BALB/c strain occur independently of the genetic and parental origin of the affected chromosomes 6, 12, and 15. 53 62
8946197 1996
47
Identification of a novel antigenic structure of the human receptor for interleukin-6 involved in the interaction with the glycoprotein 130 chain. 53 62
8911151 1996
48
Early B-cell factor (EBF) down-regulates immunoglobulin heavy chain intron enhancer function in a plasmacytoma cell line. 53 62
8693297 1996
49
Multiple cytokines inhibit interleukin-6-dependent murine hybridoma/plasmacytoma proliferation. 53 62
8599834 1996
50
Production of interleukin-6 by human mast cells and basophilic cells. 53 62
8592085 1996
Sources

Variations for Plasmacytoma

About this section
Sources

Expression for Plasmacytoma

About this section
Search GEO for disease gene expression data for Plasmacytoma.
Sources

Pathways for Plasmacytoma

About this section

Pathways related to Plasmacytoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 13.88 PTPRC OSM NCAM1 MYC LIF IL6ST
2
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.6 OSM MYC LIF IL6ST IL6R IL6
3
Prolactin Signaling 64
Show member pathways
 13.44 PTPRC MYC IL6R IL6 CD79A CCND1
4
Akt Signaling 64
Show member pathways
 13.37 OSM LIF IL6R IL6 IL11 CCND1
5
PAK Pathway 64
Show member pathways
 13.27 PTPRC OSM LIF IL6R IL6 IL11
6
Cytokine Signaling in Immune system 66
Show member pathways
 12.98 OSM NCAM1 MYC LIF IL6ST IL6R
7
PI3K-Akt signaling pathway 74
Show member pathways
 12.91 OSM MYC IL6R IL6 CCND1 BCL2
8
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.61 PTPRC MYC IL6ST IL6R IL6
9
NF-kappaB Signaling 3
12.43 PTPRC PAX5 NCAM1 IL6ST CD79A CD38
10
Breast cancer pathway 74
Show member pathways
 12.42 MYC LIF IL6ST CCND1
11
MAPK Signaling: Mitogens 65
Show member pathways
 12.17 MYC IL6ST IL6R CCND1 BCL2
12
Colorectal Cancer Metastasis 64
12.16 MYC IL6R IL6 CCND1
13
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 12.09 IL6ST IL6R IL6 CCND1
14
Neuroinflammation and glutamatergic signaling 74
12.04 LIF IL6ST IL6R IL6 BCL2
15
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 65
12 IL11 IL6 LIF MYC NCAM1
16
Adipogenesis 74
11.95 OSM LIF IL6ST IL6 EBF1
17
Senescence and autophagy in cancer 74
11.91 IL6ST IL6R IL6 BCL2
18
DNA damage response (only ATM dependent) 74
11.89 MYC CCND1 BCL2
19
Notch Signaling Pathways 65
11.88 MYC CCND1 BCL2
20
Small cell lung cancer 74
11.86 MYC CCND1 BCL2
21
Mesenchymal Stem Cells and Lineage-specific Markers 65
11.85 PTPRC NCAM1 IL6 CD79A
22
Cytokine production by Th17 cells in CF (Mouse model) 22
Show member pathways
 11.84 IL6ST IL6R IL6
23
Th17 Differentiation 65
Show member pathways
 11.83 IL6 IL6R IL6ST
24
Retinoblastoma gene in cancer 74
11.8 STMN1 MYC CCND1
25
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.8 CD38 CD79A IL11 IL6 NCAM1 PTPRC
26
C-MYB transcription factor network 61
11.76 PAX5 MYC CCND1 BCL2
27
Acute viral myocarditis 74
11.72 BCL2 CCND1 IL6
28
Dendritic Cells Developmental Lineage Pathway 65
11.72 PTPRC NCAM1 IL6 CD38
29
Extrafollicular B cell activation by SARS-CoV-2 74
11.69 CD79A IL6 PAX5 PTPRC
30
AP-1 transcription factor network 61
11.68 MYC IL6 CCND1
31
Validated targets of C-MYC transcriptional repression 61
11.63 MYC CCND1 BCL2
32
IL 10 signaling pathway 67
11.63 IL6ST IL6R IL6
33
ATF-2 transcription factor network 61
11.59 IL6 CCND1 BCL2
34
Hepatitis C and hepatocellular carcinoma 74
11.57 MYC IL6R IL6 CCND1
35
SHP2 signaling 61
11.56 IL6ST IL6R IL6
36
Interleukin-4 and Interleukin-13 signaling 66
11.53 OSM MYC LIF IL6R IL6 CCND1
37
RAF-independent MAPK1/3 activation 66
Show member pathways
 11.51 IL6ST IL6R IL6
38
Pluripotent stem cell differentiation pathway 74
11.5 IL11 IL6 IL6R
39
Interleukin-11 signaling pathway 74
11.45 IL6ST IL11 BCL2
40
IL6-mediated signaling events 61
11.41 MYC IL6ST IL6R IL6
41
Validated transcriptional targets of AP1 family members Fra1 and Fra2 61
11.34 LIF IL6 CCND1
42
IL-10 Pathway 64
11.33 MYC IL6 CCND1
43
Immune response_IL-6 signaling pathway 22
11.3 IL6ST IL6R IL6
44
Prion disease pathway 74
11.21 PAX5 NCAM1 EBF1 BCL2
45
Hair follicle development: organogenesis - part 2 of 3 74
11.15 NCAM1 MYC CCND1
46
Interleukin-6 family signaling 66
Show member pathways
 11.02 OSM LIF IL6ST IL6R IL6 IL11
47
G-protein signaling_Rap2B regulation pathway 22
10.98 BCL2 IL11 IL6 LIF OSM STMN1
48
ncRNAs involved in STAT3 signaling in hepatocellular carcinoma 74
10.88 IL6ST IL6R IL6 IL11
49
Mammary gland development pathway - Puberty (Stage 2 of 4) 74
10.81 MYC CCND1
50
Signaling mediated by p38-gamma and p38-delta 61
10.72 STMN1 CCND1
Sources

GO Terms for Plasmacytoma

About this section

Cellular components related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.77 PTPRC NCAM1 IL6ST IL6R IGKC CD79A
2 ciliary neurotrophic factor receptor complex GO:0070110 9.46 IL6ST IL6R
3 interleukin-6 receptor complex GO:0005896 9.1 IL6ST IL6R IL6

Biological processes related to Plasmacytoma according to GeneCards Suite gene sharing:

(show all 23)
# Name GO ID Score Top Affiliating Genes
1 B cell receptor signaling pathway GO:0050853 10.09 PTPRC IGKC CD79A CD38 BCL2
2 positive regulation of B cell proliferation GO:0030890 10.06 PTPRC CD38 BCL2
3 B cell proliferation GO:0042100 10.06 BCL2 CD38 CD79A PTPRC
4 response to cytokine GO:0034097 10.04 IL6ST IL6R CD38 BCL2
5 response to gamma radiation GO:0010332 10.02 PTPRC MYC BCL2
6 B cell differentiation GO:0030183 10.02 PTPRC PAX5 IL11 CD79A BCL2
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 10.02 OSM LIF IL6 IL11 BCL2
8 positive regulation of MAPK cascade GO:0043410 10 PTPRC OSM LIF IL6R IL6 IL11
9 interleukin-6-mediated signaling pathway GO:0070102 9.99 IL6ST IL6R IL6
10 positive regulation of acute inflammatory response GO:0002675 9.95 OSM IL6ST IL6
11 T-helper 17 cell lineage commitment GO:0072540 9.91 IL6R IL6
12 stem cell development GO:0048864 9.91 PTPRC BCL2
13 oncostatin-M-mediated signaling pathway GO:0038165 9.9 OSM IL6ST
14 vascular endothelial growth factor production GO:0010573 9.89 IL6R IL6
15 negative regulation of hormone secretion GO:0046888 9.88 IL11 LIF OSM
16 ciliary neurotrophic factor-mediated signaling pathway GO:0070120 9.87 IL6ST IL6R
17 interleukin-11-mediated signaling pathway GO:0038154 9.86 IL6ST IL6R
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 IL6 IL6R IL6ST LIF OSM
19 hepatic immune response GO:0002384 9.84 IL6 IL6R
20 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 PTPRC OSM LIF IL6R IL6 IL11
21 regulation of signaling GO:0023051 9.58 LIF OSM
22 positive regulation of cell population proliferation GO:0008284 9.58 OSM MYC LIF IL6ST IL6R IL6
23 regulation of cell communication GO:0010646 9.52 OSM LIF

Molecular functions related to Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ciliary neurotrophic factor receptor activity GO:0004897 9.67 IL6ST IL6R
2 interleukin-11 binding GO:0019970 9.62 IL6ST IL6R
3 interleukin-11 receptor activity GO:0004921 9.56 IL6ST IL6R
4 interleukin-6 binding GO:0019981 9.46 IL6ST IL6R
5 interleukin-6 receptor activity GO:0004915 9.26 IL6ST IL6R
6 interleukin-6 receptor binding GO:0005138 9.1 IL6ST IL6R IL6
Sources

Sources for Plasmacytoma

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....